Results 101 to 110 of about 3,972 (148)

Glioblastoma, <i>IDH-</i>wildtype, with a novel <i>MEF2D-NTRK1</i> gene fusion: a case report. [PDF]

Front Oncol
Dewey A, Baranda JC, Zhang W, Haeri M, Milligan B, Tuncer T.   +5 more
europepmc   +1 more source

Efficacy of larotrectinib in pediatric cancers with <i>NTRK</i> gene fusions. [PDF]

Transl Pediatr
Houghton PJ, Bjornsti MA.
europepmc   +1 more source

How to manage radioiodine-refractory thyroid cancer in the era of precision medicine. [PDF]

Drugs Context
Karapanou O, Effraimidis G, Michalaki M, Saltiki K.   +3 more
europepmc   +1 more source

The Evolution of Precision Oncology. [PDF]

Balkan Med J
Hacıoğlu MB.
europepmc   +1 more source

TRK inhibitors in pediatric gliomas. [PDF]

Neurooncol Adv
Perreault S, Doz F.
europepmc   +1 more source

Advancing the treatment of NTRK-fused pediatric solid tumors: lessons from the ADVL1823 study. [PDF]

Transl Pediatr
Vince CSC, Valera ET.
europepmc   +1 more source

Harnessing machine learning models to repurpose drugs targeting HIV-1 integrase, protease, and reverse transcriptase. [PDF]

Sci Rep
Chirila CB, Crisan L.
europepmc   +1 more source

Clinical Benefit From Molecularly Guided Cancer Care: A Matching-Adjusted Indirect Comparison of Larotrectinib Versus Standard of Care. [PDF]

JCO Precis Oncol
Bokemeyer C, Abrams KR, Garcia-Foncillas J, Italiano A, Lassen U, Linsell L, Marian M, Paracha N, Sullivan SD, Brega N, Thompson J.   +10 more
europepmc   +1 more source

<i>NTRK1-3</i> fusions in sarcomas: prevalence, significance, and clinical implications - a systematic review. [PDF]

Future Oncol
Hamran S, Alnoubani Z, Hassan AM, Al-Rajhi AA, Rajha HE, Altaissan M, Babu GR, Gatalica Z, Vranić S.   +8 more
europepmc   +1 more source

Minimal residual disease assessment through ctDNA facilitates tailored immunotherapy in MSI-high, NTRK1-fusion pancreatic adenocarcinoma. [PDF]

Oncologist
Rohlfing S, Vladimirova D, Berger S, Bochum S, Otmacic G, Weiß M, Sipos B, Biskup S, Klaumünzer M, Martens UM.   +9 more
europepmc   +1 more source